CTXR
Citius·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 2
Consensus Rating "Strong Buy"
MACD Death Cross
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CTXR
Citius Pharmaceuticals, Inc.
A late-stage biopharmaceutical company that developing and commercializing first-in-class critical care products
11 Commerce Drive, First Floor, Cranford, NJ 07016
--
Citius Pharmaceuticals, Inc., was incorporated on January 23, 2007 as Citius Pharmaceuticals, LLC, a Massachusetts limited liability company. Headquartered in Cranford, NJ, the Company is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products for critical medical needs, with a focus on anti-infective products and unique prescription products in adjuvant cancer care. The company's goal is to achieve a leading market position by providing therapeutic products that address unmet medical needs. New formulations of previously approved drugs with extensive safety and efficacy data are a core focus as companies seek to reduce development and clinical risks associated with drug development. The company's strategy centers on products with intellectual property and regulatory protection, while providing a competitive advantage over existing treatments.
Company Financials
EPS
CTXR has released its 2025 Q3 earnings. EPS was reported at -0.8, versus the expected -0.21, missing expectations. The chart below visualizes how CTXR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
